MicroCNX connectors are a critically important option for a range of bioprocessing, cell therapy and gene therapy workflows,.”Until now, cumbersome tube welding has been the only way to make sterile closed connections of very small-bore tubing. The MicroCNX connector represents a huge innovation for the industry.
Proposed acquisition of Trillium strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
Signature Biologics, LLC., today announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics’ transparency in doing business with open floor plan and floor-to-ceiling views into its fully equipped manufacturing and R&D laboratory spaces.
ACROMEC Limited (“ACROMEC”, SGX:43F), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biomedical, research and academia sectors, has secured three new contracts totaling approximately S6.2 million.
Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the completion of a €47 million financing round (~US$55 million) to advance its lead program into clinical development. Andera Partners (formerly Edmond de Rothschild Investment Partners) led the financing round, joined by Pontifax, Bpifrance, Kurma Partners and IdInvest Partners.
pharmaceutical plant in Skidel (Grodno Oblast) will be launched in October, the press service of the Council of Republic told BelTA following the meeting between Speaker, curator of the Belarusian-Indian cooperation Mikhail Myasnikovich and Indian investors Jayant Kaushik, Alok Kumar (Lok-Beta Pharmaceuticals (I) Pvt. Ltd) and Director of OOO Novalok Kumar Manoranjan.
R&D Operations Hub to Open in Chengdu, China Sanofi to further accelerate its scientific presence with the opening...
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division.
Russian researchers from the Moscow Institute of Physics and Technology have developed biosensor chips of unprecedented sensitivity, which are based on copper instead of the conventionally used gold. Besides making the device somewhat cheaper, this innovation will facilitate the manufacturing process.
Bayer Strategic Partnership formed. Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases such as heart failure.
An international team has developed a ground-breaking single-electron “pump”. The electron pump device developed by the researchers can produce one billion electrons per second and uses quantum mechanics to control them one-by-one. And it’s so precise they have been able to use this device to measure the limitations of current electronics equipment.
University of Glasgow’s Professor Ravinder Dahiya has plans to develop ultra-flexible, synthetic Brainy Skin that ‘thinks for itself’. The super-flexible, hypersensitive skin may one day be used to make more responsive prosthetics for amputees, or to build a robotic hand with a sense of touch.